Cover photo
Forex broker | Boston Merchant Financial (BMFN)
132 followers|26,345 views
Global Markets Delivered Locally.
We are the market leading online forex trading broker and offer a wide selection of various financial products to individual and corporate customers worldwide. 

Get instant access to 12,000 financial instruments around the world including prices on stocks, indices, currencies, and commodities. 

  • We have a platform and account to suit any experience or requirement 
  • Customer support par excellence 
  • Trade commodities, margin FX, CFDs, shares, indices and many more 
  • Market leading spreads & trade execution 
  • Trusted globally by institutional and retail customers as one of the largest brokers 
  • Global presence and regulated in many jurisdictions 
  • Personal service, 1 on 1 support 

With a BMFN brokerage account you can experience and trade the Global Financial Markets from anywhere in the world; all from a single screen. 

We truly deliver GLOBAL MARKETS- LOCALLY. With offices across the globe and online trading platforms in 17 languages, we deliver access to the global financial markets 24 hours a day, 6 days a week.
Contact Information
Contact info
+1 514 667 8470, +359 2 491 7016


Asia stocks head for weekly loss, China yuan hits four-and-a-half-year low
‪#‎stocks‬ ‪#‎forex‬
Asian shares were set for sizable weekly losses, with equities faltering again on Friday as plunging crude oil prices and a tumble in China's yuan to almost 4-1/2-year lows added to worries about receding global growth.
A supply glut in oil markets and cooling growth in China, the world's biggest commodities consumer, have pressured many asset markets ahead of a widely expected hike to U.S. interest rates by the Federal Reserve next week.
MSCI's broadest index of Asia-Pacific shares outside Japan .MIAPJ0000PUS erased early modest gains and was down about 0.6 percent, facing a nearly 3 percent weekly loss.
The gloom was expected to carry into European trading, with financial spreadbetters predicting Britain's FTSE 100 .FTSE would open down by as much as 0.3 percent. Germany's DAX .GDAXI was seen as much as 0.1 percent lower, while France's CAC .FCHI expected to shed up to 0.3 percent.
The People's Bank of China (PBOC) set its guidance rate at the weakest level in more than four years on Friday, a sign Beijing is permitting the currency to depreciate after it was included in the International Monetary Fund's reserve basket.
The lower fixings have also raised questions about how far the central bank intends to let it depreciate.
In the spot market, the yuan CNY=CFXS was changing hands at 6.4499, after taking out its August low hit after the unexpected devaluation of the Chinese currency and marking its lowest level since the middle of 2011.
"A U.S. rate hike would have a major impact on money flows out of emerging markets including Hong Kong and China," said Linus Yip, chief strategist at First Shanghai Securities.
"Also, if the yuan continues to depreciate, that's negative to stocks as well, because it means investors are not confident about China's economic restructuring."
Chinese shares were lower ahead of a spate of economic data scheduled to be released on Saturday. ECONCN
The CSI300 index .CSI300 of the largest listed companies in Shanghai and Shenzhen was down 0.5 percent, while the Shanghai Composite Index .SSEC shed 0.7 percent.
Also weighing on the market mood were media reports that Guo Guangchang, chairman and founder of Chinese conglomerate Fosun, could not be reached.
Japan's Nikkei stock index .N225 bucked the trend, buoyed by overnight gains on Wall Street and a weaker yen, and ended up 1 percent. But it was still logged a loss of 1.4 percent for the week.
The dollar index .DXY, which tracks the U.S. unit against a basket of six major rivals, edged up slightly to 97.953. But it was on track for a weekly loss of about 0.4 percent after investors trimmed dollar-long positions ahead of next week's U.S. Federal Reserve meeting at which the central bank is widely expected to hike interest rates for the first time in nearly a decade.
Fed fund futures place an 85 percent chance of the Fed raising rates at its Dec. 15-16 meeting. A recent Reuters poll also showed that all but one of 18 brokerages that deal directly with the Fed expect a rate increase.
The euro EUR= edged up about 0.1 percent to $1.0947, up about 0.6 percent for the week after comments from the European Central Bank's Ewald Nowotny this week raised doubts about the extent to which U.S. and European monetary policy will diverge.
The dollar added 0.3 percent against its Japanese counterpart to 121.95 JPY= but was still down around 0.9 percent for the week.
Despite this week's softer dollar, crude oil futures continued to wallow close to 2009 lows on oversupply fears. U.S. crude CLc1 fell 0.6 percent to $36.55 a barrel. Brent LCOc1 skidded 0.6 percent to $39.49.
South Africa's rand, meanwhile, plumbed record lows against the U.S. dollar after the abrupt dismissal of respected Finance Minister Nhlanhla Nene to make room for an ally of President Jacob Zuma.
The rand ZAR= sunk as low as 15.4895 against the greenback, and was last at 15.4480.
(Additional reporting by Samuel Shen and Pete Sweeney in Shanghai; Editing by Shri Navaratnam and Eric Meijer)
Add a comment...
The largest expo Shanghai Money Fair Show and Miss UniTrader Show in Shanghai, China 2015
‪#‎Shanghai‬ ‪#‎China‬ ‪#‎expo‬ ‪#‎UniTrader‬ ‪#‎MissUniTrader‬ ‪#‎Miss‬ ‪#‎BMFN‬ ‪#‎Forex‬ ‪#‎Broker‬ ‪#‎FashionShow‬
Add a comment...
#‎forex_news‬ ‪#‎top_news‬
Goldman Sachs Downgrades Valeant After Market's Loss of Confidence

Goldman Sachs is throwing in the towel on Valeant Pharmaceuticals.
Gary Nachman, the number two-rated analyst who covers the stock, lowered his recommendation on the troubled Canadian pharmaceutical company to "neutral" from "buy" and slashed his price target to $122 from $180. He had maintained a buy rating since November 30, 2014.
Since October 16, Valeant's share price has been nearly cut in half, coming in at $93.77 as of Friday's close after Citron Research's Andrew Left suggested that it could be the pharmaceutical industry's equivalent to Enron. The company's subsequent disclosures appear to have failed to adequately placate nervous investors.
While Nachman notes that Valeant's fundamentals may support a higher valuation, the controversy surrounding the company means that its share price won't be a product of these fundamentals for the foreseeable future.
"Given the events that have transpired very rapidly in recent weeks that have raised many questions about certain aspects of VRX’s business model, we have less confidence the market will reward the stock anytime soon without clarity as to the path forward," wrote Nachman. "We move to the sidelines until there is further visibility on how management will repair the reputational damage to the company, as well as grow its business effectively in this increasingly challenging environment."
Nachman expressed surprise that the market did not react more favorably to Valeant's decision to sever ties with Philidor, the company whose unusual relationship with Valeant has raised eyebrows.
This affair will put pressure on Valeant's financial performance from both sides, the analyst believes. Nachman downgraded his estimates for revenue growth through 2019 to account for the end of Valeant's relationship with Philidor, and also reduced his forecasts for earnings per share in light of "modestly higher [operating expenditure] to improve VRX's profile as a pharma company."
The Canadian pharmaceutical company does enjoy some ties with Goldman Sachs.
Former chief financial officer and board member Howard Schiller, praised as a driving force behind the company's growth-by-acquisition strategy, spent over two decades at the investment bank prior to his time at Valeant. Goldman has also long served as an adviser, lender, and underwriter for Valeant Pharmaceuticals, though it has not arranged financing since 2013.
Add a comment...
Meet VALERIA. For more information about her and the other#MissUniTrader contestants see
I am the student of the National Kyiv-Mohyla University. I have a healthy lifestyle. I really admire sport and different kinds of activities. I work as a tutor of English for children. Moreover, I am very hard-working, persistent, responsible, sociable and intelligent. I believe that everyone should develop itself in the purpose of achieving the necessary aims. If I have some troubles, I do not despair and try to fight the difficulties by using m...
Add a comment...
4 Best Internet Of Things Stock Buys
‪#‎stocks‬ ‪#‎forex‬
This story appears in the December 28, 2015 issue of Forbes. Subscribe
The Internet of Things is easily the most overhyped technology advance of the last 2,000 years. It’s less important than agriculture, the internal combustion engine, the electric light, the airplane, antibiotics, wireless phones, space travel, the Internet itself and, arguably, sugarless gum.
But it’s still incredibly important and could represent one of the most lucrative investment opportunities of our lifetime.
Connecting every tangible item and every person in an immersive web of dynamic intelligence over the next 15 years will yield stunning productivity, environmental, medical, entertainment and human benefits.
The new connective mesh could usher in the sort of utopian “hive mind” imagined by science fiction and currently practiced by bees and ants in which no keys are ever lost, no fact unremembered and no communications unsent. Imagine a mind-blowing state of total awareness.
With changes so massive coming you would think it would be easy to figure out how to take advantage. Most white papers at think tanks focus on the connectivity of the things, such as network equipment and sensors. And, to be sure, the recent spate of big semiconductor mergers–i.e., Avago buying Broadcom, Intel buying Altera and NXP Semi buying Freescale–are aimed at scaling up to dominate this next phase of profound connectivity.
Yet most of the value of this brave new world will be in the software that compiles, analyzes and gives meaning to the data collected by billions of sensors and seamlessly knits together objects and people. You might even say that the best Internet of Things projects won’t be products at all. They will be services that help us navigate the physical and online worlds with less friction and more joy. The easy software bets in this space are platform toll-takers like the Amazon Web Services and the Azure cloud services unit of Microsoft. But for aggressive investors, the smart bet will be in smaller, cutting-edge software and design companies that help clients bend and blend the worlds of sensors, marketing, connectivity, the cloud and aesthetics for customers’ benefit.

One of the most intriguing along these lines is Globant (GLOB, 36), a little-known technology design and engineering firm that went public in mid-2014 at $10 and has since quietly tripled, where it sports a modest $1.2 billion market cap and a forward price/earnings multiple of 32 times.
Add a comment...